A single centre retrospective study of the long‑term weight and pregnancy-related outcomes in women of reproductive age before and after liraglutide exposure
Authors' conclusion
Preconception liraglutide exposure, followed by discontinuation before pregnancy, was associated with weight regain but not with excess gestational weight gain in our within-individual design. Despite a small sample size, we did not observe increased adverse gestational outcomes in the post-exposure pregnancies.
Study context
- Population
- Women of reproductive age initiated on liraglutide for obesity management with 2–5 years of follow-up
- Participants
- 556 women
- Exposure
- Pregnancies before vs after liraglutide exposure in the same women; women who conceived vs did not after liraglutide
- Conceivedn = 97
- Did not conceiven = 459reference
- Outcome
- Mean final weight change
- Follow-up
- 2-5 years
Methodological detailssingle-centre, within-individual design
- Single-centre
- Within-individual design
Main finding
As reported in the abstract
Conceived
+1.1
mean · SD 11.3 · %
Did not conceive
−6.7
mean · SD 9.9 · %
P < 0.001
Observational data: associations, not effects.
Further findings
Inconsistent obesity medication use during study period
| Outcome | P value |
|---|---|
| Gestational weight change, pre- vs post-exposure pregnancies | P = 0.554 |
| GDM, pre- vs post-exposure pregnancies | P = 0.629 |
| Gestational weight gain with vs without metformin use during pregnancy (subgroup) | P = 0.369 |
- Nadir weight reduction on liraglutide in women who conceived
- −6.2 · SD 7.8 · %
- Gestational weight change, pre- vs post-exposure pregnancies: Pre-exposure 8.0 (SD 10.9) %
- Gestational weight change, pre- vs post-exposure pregnancies: Post-exposure 9.2 (SD 11.8) %
- GDM, pre- vs post-exposure pregnancies: Pre-exposure 32.1%
- GDM, pre- vs post-exposure pregnancies: Post-exposure 37.7%
- Gestational weight gain with vs without metformin use during pregnancy (subgroup): Metformin 5.8 (SD 9.1) kg
- Gestational weight gain with vs without metformin use during pregnancy (subgroup): No metformin 8.2 (SD 9.5) kg
Safety
Hypertensive disorders of pregnancy
P = 0.063
C-section
P = 0.549
Pre-term delivery
P = 0.500
Large for gestational age
P = 1
Small for gestational age infants
P = 1
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →